在现实世界2型糖尿病患者中,访问对访问的脂质变化和不良事件
Hsuan-Yu Su1, Yi-Hsin Chang1, Chen-Yi Yang1
1Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Diabetes research and clinical practice
|March 12, 2025
概括
低密度脂蛋白胆固醇 (LDL-C) 的更大变化增加了2型糖尿病患者的脏事件风险. 监测LDL-C稳定性对于预防脏不良结果至关重要.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
背景情况:
- 2型糖尿病 (T2D) 是慢性病的主要原因.
- 在T2D管理中,管理脂质特征,特别是LDL-C,至关重要.
- 对于LDL-C可变性对T2D中脏结果的影响尚未完全理解.
研究的目的:
- 研究T2D患者的长期LDL-C变化和脏不良事件之间的关联.
- 为了确定特定的LDL-C可变度指标,预测病进展.
- 探索患有LDL-C波动风险较高的患者子组.
主要方法:
- 分析了15444名T2D患者的队列.
- 事件包括持续的eGFR<15mL/min/1.73m2,30%的eGFR下降,以及复合事件.
- 考克斯的比例危险模型评估了LDL-C可变性指数和事件之间的关系.
主要成果:
- 增加的LDL-C变异性与较高的事件风险相关,除了变化系数.
- 平均真实变化 (ARV) 显示了持续EGFR<15mL/min/1.73m2 (切断点19.26) 的强有力的预测性能.
- 较年轻的患者 (<75岁),EGFR≥90mL/min/1.73m2的患者,以及较少的糖尿病并发症患者中,LDL-C变异性风险较高.
结论:
- 访问到访问的LDL-C变异性是T2D中脏不良事件的独立风险因素.
- 除单点测量外,随着时间的推移监测LDL-C稳定性在临床上具有意义.
- 这些发现强调了管理脂质波动对于T2D中脏保护的重要性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Symptoms, Diagnosis, and Complications
495
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
495
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
496
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
496
Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153
Insulin: Dosing Regimen and Adverse Effects
135
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
135
Diabetes: Management and Pharmacotherapy
220
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
220


